메뉴펼치기
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
해당 자료는 2페이지 까지만 미리보기를 제공합니다.
2페이지 이후부터 다운로드 후 확인할 수 있습니다.
2페이지 이후부터 다운로드 후 확인할 수 있습니다.
본문내용
non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology. 2001;33:455-63. [PMID: 11172349]
21. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002;36:S121-7. [PMID: 12407585]
[Author Affiliation]
Miriam J. Alter, PhD; Leonard B. Seeff, MD; Bruce R. Bacon, MD; David L. Thomas, MD; Michael O. Rigsby, MD; and Adrian M. Di Bisceglie, MD
[Author Affiliation]
From National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland; American Association for the Study of Liver Diseases and The Infectious Diseases Society of America, Alexandria, Virginia; Veterans Health Administration, Department of Veterans Affairs, Washington, DC; and Hepatitis Council, American Liver Foundation, New York, New York.
Acknowledgments: The authors thank Jay H. Hoofnagle, MD, National Institutes of Health, Bethesda, Maryland, and John C. McHutchison, Duke University Medical Center, Durham, North Carolina, for their valuable contributions to this manuscript.
Potential Financial Conflicts of Interest: Consultancies: A.M. Di Bisceglie (Schering-Plough, Roche, Idenix, SciClone Pharmaceuticals, Chiron Corp., Vertex, 3M); Honoraria: D.L. Thomas (Roche, Schering-Plough), A.M. Di Bisceglie (Schering-Plough, Roche); Grants received: A.M. Di Bisceglie (Schering-Plough, Roche, Idenix, SciClone Pharmaceuticals); Other: D.L. Thomas (Chiron Corp., Roche).
Requests for Single Reprints: Miriam J. Alter, PhD, Division of Viral Hepatitis, Mailstop D66, Centers for Disease Control and Prevention, Atlanta, GA 30333.
Current author addresses are available at www.annals.org.
21. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology. 2002;36:S121-7. [PMID: 12407585]
[Author Affiliation]
Miriam J. Alter, PhD; Leonard B. Seeff, MD; Bruce R. Bacon, MD; David L. Thomas, MD; Michael O. Rigsby, MD; and Adrian M. Di Bisceglie, MD
[Author Affiliation]
From National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland; American Association for the Study of Liver Diseases and The Infectious Diseases Society of America, Alexandria, Virginia; Veterans Health Administration, Department of Veterans Affairs, Washington, DC; and Hepatitis Council, American Liver Foundation, New York, New York.
Acknowledgments: The authors thank Jay H. Hoofnagle, MD, National Institutes of Health, Bethesda, Maryland, and John C. McHutchison, Duke University Medical Center, Durham, North Carolina, for their valuable contributions to this manuscript.
Potential Financial Conflicts of Interest: Consultancies: A.M. Di Bisceglie (Schering-Plough, Roche, Idenix, SciClone Pharmaceuticals, Chiron Corp., Vertex, 3M); Honoraria: D.L. Thomas (Roche, Schering-Plough), A.M. Di Bisceglie (Schering-Plough, Roche); Grants received: A.M. Di Bisceglie (Schering-Plough, Roche, Idenix, SciClone Pharmaceuticals); Other: D.L. Thomas (Chiron Corp., Roche).
Requests for Single Reprints: Miriam J. Alter, PhD, Division of Viral Hepatitis, Mailstop D66, Centers for Disease Control and Prevention, Atlanta, GA 30333.
Current author addresses are available at www.annals.org.
추천자료
- 가격1,000원
- 페이지수8페이지
- 등록일2005.04.03
- 저작시기2005.04
- 파일형식한글(hwp)
- 자료번호#1138768
본 자료는 최근 2주간 다운받은 회원이 없습니다.
소개글